Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer
Journal of Biological Chemistry · 2026
DOI: 10.1016/j.jbc.2026.111447 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2026. Verfasst von Chenxiao Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China; Departm…. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Cisplatin, Drug Resistance, Neoplasm, RNA-Binding Proteins. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Province Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Platinum-resistant is a major therapeutic challenge in advanced endometrial cancer (EC), often driven by enhanced DNA damage repair, yet the underlying molecular mechanisms remain incompletely understood. Here, we report that cyclin-dependent kinase 13 (CDK13) is significantly overexpressed in EC tissues, where its high expression correlates with poor patient survival and clinical resistance to platinum-based chemotherapy. Functionally, CDK13 overexpression promoted EC cell proliferation and conferred cisplatin resistance both in vitro and in vivo, whereas its knockdown potentiated cisplatin-induced apoptosis and DNA damage. Mechanistically, through phosphoproteomic analysis, we identified the RNA-binding protein RNA-binding motif protein 39 (RBM39) as a critical downstream target of CDK13. We demonstrate that CDK13 directly phosphorylates RBM39 at serine 117, and this phosphorylation is essential for CDK13-mediated resistance. Crucially, phosphorylation at Ser117 enhanced the ability of RBM39 to bind and stabilize the mRNA of RAD50, a key DNA repair gene. Post-transcriptional regulation led to an increase in RAD50 protein, which facilitated the repair of DNA damage caused by cisplatin, promoting the survival of cells. The therapeutic relevance of this axis was confirmed in vivo, where dual knockdown of RBM39 and RAD50 synergistically sensitized EC xenografts to cisplatin. Our study first unveils a novel CDK13/RBM39/RAD50 signaling axis that drives platinum resistance in EC by enhancing DNA damage repair via mRNA stabilization, revealing promising therapeutic targets for overcoming chemoresistance in this malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China; Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao U…
- Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China.
- Center of Tumor Immunology and Cytotherapy, Medical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
- Department of Obstetrics and Gynecology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Electronic address: yuanfangdoctor@126.com.
Förderung
- Shandong Province Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Yang, C., Zheng, X., Sun, H., Du, J., Luo, Y., Wang, C., Wu, Y., Qu, L., Yuan, F., & Yang, Z. (2026). Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2026.111447
Vancouver
Yang C, Zheng X, Sun H, Du J, Luo Y, Wang C, et al. Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer. Journal of Biological Chemistry. 2026. doi:10.1016/j.jbc.2026.111447
BibTeX
@article{Yang2026,
author = {Yang, Chenxiao and Zheng, Xiaoyan and Sun, Hao and Du, Juntong and Luo, Youjun and Wang, Chang and Wu, Yunlong and Qu, Liying and Yuan, Fang and Yang, Zhan},
title = {Phosphorylation of RBM39 by CDK13 stabilizes RAD50 mRNA to drive cisplatin resistance in endometrial cancer},
journal = {Journal of Biological Chemistry},
year = {2026},
doi = {10.1016/j.jbc.2026.111447}
}
EUVIMED